Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025
Tuberculous Meningitis
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- Not specified - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 300 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
TBM Study is a multicenter, observational, retrospective cohort study of Tuberculous Meningitis (TBM) patients who underwent treatment at the hospital during the 2022-2025 period. The goal of this study is to learn about the clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes of patients diagnosed with TBM who were admitted to the study hospitals between 2022 and 2025. This study uses retrospective data obtained from electronic medical records (EMR).
Read the full description
Participants who admitted to the participating hospital sites between January 1, 2022, and December 31, 2025, have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system, and have accessible data available in the EMR will be enrolled to this study. The data will be collected at five timepoints:
Timepoint 1: Hospital Admission Timepoint 2: TB Treatment Initiation Timepoint 3: Hospital Discharge Timepoint 4: End of Intensive Phase Timepoint 5: End of Treatment
Six hospitals participate as the study sites. They are:
1. RS Penyakit Infeksi Prof. Dr. Sulianti Saroso (RSPI SS), Jakarta
2. RS Pusat Otak Nasional Prof. Dr. dr. Mahar Mardjono (RSPON), Jakarta
3. RSUP dr Mohammad Hoesin, Palembang
4. RSUP dr M Djamil, Padang
5. RSUP Prof Dr I.G.N.G. Ngoerah, Denpasar
6. RSUP dr Johannes Leimena, Maluku
No biological specimens will be collected as part of the study. Data will be extracted from electronic medical records (EMR) at the study participating hospitals. Patient data will be collected from existing records at predefined time points through the end of treatment.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Admited to the participating hospital sites between January 1, 2022, and December 31, 2025
- Have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system.
- Have accessible data available in the EMR.
Exclusion Criteria:
None
Study population
The population of this study consists of patients diagnosed with TBM who were admitted to participating hospital sites. Eligible cases will be identified through hospital EMR systems using the ICD-10 code A17.0 or based on a documented diagnosis of TBM in the EMR and will be verified by clinical documentation.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
No intervention (observational study) OTHER
No intervention (observational study)
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
The proportion of TBM cases across TBM categories of clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
Not reported in this registry record.
Secondary measures
To estimate the annual trend of TBM admissions at the hospitals from 2022 to 2025
Time frame: at hospital admission timepoint
Not reported in this registry record.
The proportion of TBM cases across comorbidities, concurrent pulmonary or extrapulmonary tuberculosis, and co-infections according to the Marais consensus diagnostic criteria
Time frame: During hospitalization, an average 2 weeks
Not reported in this registry record.
The proportion of TBM cases across use and diagnostic yield of laboratory investigations and neuroimaging modalities according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
Not reported in this registry record.
The proportion of TBM cases across factors associated with in-hospital mortality, end-of treatment outcome, and neurological sequelae according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
Not reported in this registry record.
The proportion of TBM cases across post-discharge follow-up status and final treatment outcomes, including treatment completion, death, loss to follow-up (LTFU), and presence of neurological sequelae according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
Not reported in this registry record.
The proportion of TBM disease severity, treatment, and outcomes, based on age group, HIV status, drug resistance status
Time frame: During TB treatment, an average 8-12 months
Not reported in this registry record.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (6)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
6 locations
Site 520: RSUP Prof Dr I.G.N.G. NgoerahDenpasar, Bali, IndonesiaNot yet recruiting
Site 701: RS Pusat Otak Nasional Prof. Dr. dr. Mahar Mardjono (RSPON)Jakarta, DKI Jakarta, IndonesiaRecruiting
Site 540: RS Penyakit Infeksi Prof. Dr. Sulianti Saroso (RSPI SS)Jakarta, DKI Jakarta, IndonesiaRecruiting
Site 704: RSUP dr Johannes LeimenaAmbon City, Maluku, IndonesiaRecruiting
Site 702: RSUP dr Mohammad HoesinPalembang, South Sumatra, IndonesiaRecruiting
Site 703: RSUP dr M DjamilPadang, West Sumatra, IndonesiaRecruiting
Study team and timeline
- Lead sponsor
- Ina-Respond
- Study start
- Sep 24, 2026 Actual
- Primary completion
- Aug 31, 2027 Estimated
- Study completion
- Dec 31, 2027 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis: A Retrospective Cohort Study in Indonesia, 2022-2025
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026